Structuring diabetes services has become necessary in order to improve the treatment of diabetes and to support the diabetes care team. Studies have shown that the use of an Integrated Care System (ICS) for diabetes has resulted in significant reductions in emergency-department visits and hospitalisations. It also positively affects the lowering of secondary complications.

The Portavita Diabetes Module has been developed in close cooperation with GPs, internists, paramedics, nursing staff and patients’ associations.

Together with leading international universities and hospitals we continuously work on the improvement of the software. When new trends come up that make a positive contribution to the treatment of diabetic patients, we have the technical ability to integrate them in our software.

This includes, for instance, the integration of data from sensors or genetic data in our Care Management Modules. We work closely together with European universities and enterprises on these innovations within European projects such as Commodity12.

By supporting collaboration between all healthcare providers and the patient, the Portavita Diabetes Module enables you to monitor diabetes patients closely. The system aims to improve the quality of diabetes care and to prevent complications.

All those involved in diabetes care can be authorised to make a specific contribution to the treatment. The level of authorisation depends on the different roles and responsibilities allocated to the relevant health care providers. This allows you to delegate specific tasks to those parties who are most appropriate to carry out such tasks.
The software also supports diabetes self-management.

Advantages of the Diabetes Module:

  • The monitor screen shows the condition of a patient at a glance.
  • As soon as an examination has been approved, it is available in real time for other authorised users.
  • Patients themselves have access to their personal health information.
  • Patients can add information to the system and share this information with all relevant healthcare providers.
  • Patients have access to their personal care plan with their own treatment goals.
  • Information from wearables and other sensors can be added to the ICS.
  • Management reporting displays insights on a patient level, practice level and regional level.
  • All data that has been registered can be used to support the financial process.
  • The Portavita Diabetes Module can be used on any Internet connected device at any time from any place.
  • The Portavita Diabetes Module is integrated with other Portavita Care Management Modules, such as Asthma/COPD, CVRM, Palliative and Elderly Care.

All patients have access to the Integrated Care System through their own secure patient portal.

As part of the Portavita Diabetes Module, patients can:

  • keep their glucose diary up-to-date;
  • safely exchange information with their therapists by using e-consultation messages;
  • view results of examinations;
  • read what was discussed during a consultation.

A recent study by the Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, showed that patients who use the Portavita Digital Log value the system with a score of 8 out of 10.

Continuous monitoring by sensors is on the rise. There are a lot of different technologies in development for monitoring diabetic patients in this new ‘quantified self’ manner. We believe that this innovation will contribute significantly to a better treatment of diabetes.

For this reason we are working closely together with leading European universities, hospitals and companies, to make our software available for this revolutionary upcoming trend. Information obtained from a variety of sources, including sensors, can be automatically uploaded in the Portavita Diabetes Module. This includes, among other, information on:

  • weight;
  • glucose levels;
  • heart rate;
  • blood pressure;
  • respiration.

The Portavita software provides continuous analysis of all data from various sources and direct feedback to both the physician and the patient.

Since October 2011, Portavita has also been participating in the COMMODITY12 research project. In COMMODITY12 we build a multi-layered multiparametric infrastructure for continuous monitoring of diabetes type 1 and 2. The COMMODITY12 system will exploit multiparametric data to provide healthcare providers and patients with clinical indicators for the treatment of diabetes type 1 and 2. The use of data, acquired through continuous monitoring by sensors that are attached to the patients’ skin and that continuously pass on specific values to the system, is an important part of this project. The project is partly financed by the European Commission within the framework of the FP7 programme.